922results about "Haemofiltration" patented technology

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Methods for aspiration to remove thrombus / clot material using a system configured to remove, filter and return clot. These methods allow the removal of clot material using a fluidically-driven aspiration device when attached to an aspiration catheter and proximate to obstructive clot material. A fluidic actuator drives an aspirator, which may be automatically controlled to apply a vacuum in a pattern to enhance clot removal and collection from the body as well as improve blood return using the same closed system. The fluidic actuator may direct the aspirated blood through a filter and deaerator to allow the filtered blood to be returned to the patient.

The present disclosure relates to a membrane prepared from a blend comprising i) a polysulfone, polyether sulf one or polyarylethersulfone and ii) polyvinylpyrrolidone, characterized in that the membrane is coated with polydopamine and chon-droitin. Optionally the coating further comprises heparin. The disclosure further relates to a process for producing the coated membrane, a method of increasing the selectivity of a membrane, and to a filtration / diffusion device comprising the membrane which can be used, for example, in hemodialysis applications.

Components for a medical infusion fluid handling system, such as an APD system, in which one or more lines (such as solution lines), spikes or other connection ports may be automatically capped and / or de-capped. This feature may provide advantages, such as a reduced likelihood of contamination since no human interaction is required to de-cap and connect the one or more lines, the spikes, or the other connection ports. For example, a fluid handling cassette may include one or more caps that cover a corresponding spike and include a raised and / or recessed feature to assist in removal of the one or more caps from the cassette. A solution line cap may include a hole and a recess, a groove or other feature to engage with a spike cap and enable removal of the spike cap.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

The present disclosure includes systems and methods for hemodialysis, such as including a first dialysis module and an auxiliary module detachably connectable to the first dialysis module. The first dialysis module can include a dialyzer, a blood circuit, a dialysate circuit, and a sorbent. The auxiliary module can include an ultrafiltrate collector operably couplable to the dialysate circuit for removing excess fluid therefrom.

The present invention provides a method of removing microplastics from blood or body of a subject, including one or more tissues of the subject, by extracorporeal blood purification, including by plasma exchange, such as double filtration plasma exchange. The present invention also provides a method of treating medical conditions and methods of improving healthy lifespan and lifespan using extracorporeal blood purification, including plasma exchange, such as double filtration plasma exchange, such as by filtering microplastics from blood, and removing microplastics from a tissue or body of a subject, such as a human subject.

A method includes detecting a startup of an apheresis machine; in response to detecting start up, transmitting data to a server; determining, based on the data, whether software of the apheresis machine is current; receiving, in response to the data, a response from the server; and preventing usage of apheresis machine if the response indicates the software is not current. The data transmitted to the server may include one or more of a data log, a firmware version identifier, and an error log. The response may include a lockout signal. The response may include a software update. The software update may include a firmware update. The method may include automatically initiating installation of the software update. The method may include ceasing prevention of usage of the apheresis machine following installation of the software update.

Systems and methods are disclosed for peritoneal dialysis. In an illustrative example, a peritoneal dialysis system can include an input lumen that receives a fluid from a first portion of a peritoneal cavity of a patient. The peritoneal dialysis system includes a filter that filters the fluid to produce a filtered fluid and a waste product. The peritoneal dialysis system includes a mixer that adds a predetermined amount of at least one electrolyte to the filtered fluid to produce a dialysate. The peritoneal dialysis system includes a sensor that measures one or more characteristics of the dialysate, and a controller that compares the one or more characteristics to one or more dialysate characteristic thresholds to verify that the dialysate satisfies one or more rules. The peritoneal dialysis system includes an output lumen that provides the dialysate to a second portion of the peritoneal cavity of the patient.

Components for a medical infusion fluid handling system, such as an APD system, in which one or more lines (such as solution lines), spikes or other connection ports may be automatically capped and / or de-capped. This feature may provide advantages, such as a reduced likelihood of contamination since no human interaction is required to de-cap and connect the lines, spikes or other connections. For example, a fluid handling cassette may include one or more caps that cover a corresponding spike and include a raised and / or recessed feature to assist in removal of the cap from the cassette. A solution line cap may include a hole and recess, groove or other feature to engage with a spike cap and enable removal of the cap.

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

Dialysis systems are disclosed comprising new fluid flow circuits. Systems may include blood and dialysate flow paths, where the dialysate flow path includes balancing, mixing, and / or directing circuits. Dialysate preparation may be decoupled from patient dialysis. Circuits may be defined within one or more cassettes. The fluid circuit fluid flow paths may be isolated from electrical components. A gas supply in fluid communication with the dialysate flow path and / or the dialyzer able to urge dialysate through the dialyzer and urge blood back to the patient may be included for certain emergency situations. Fluid handling devices, such as pumps, valves, and mixers that can be actuated using a control fluid may be included. Control fluid may be delivered by an external pump or other device, which may be detachable and / or generally rigid, optionally with a diaphragm dividing the device into first and second compartments.

A blood reintroduction system can include a canister having a chamber configured to collect blood. A system may include an inlet configured to fluidically connect the chamber to a first tubing in fluid communication with an aspiration catheter. A system may include a first filter within the chamber, wherein the first filter is configured to separate blood from thrombus. A system may include a second filter downstream of the first filter, wherein the second filter is configured to separate blood from thrombus. A system may include a second tubing connected to an outlet of the chamber, wherein the second tubing is configured to reintroduce filtered blood from the chamber to a patient's vasculature.

The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and / or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.

The invention provides an extracorporeal circulation system which comprises a blood pumping device used for driving blood to flow in the extracorporeal circulation system; the filtering device is used for removing impurities in the blood; the heating device is used for adjusting the temperature of the blood; the gas exchange device is used for adjusting the gas content in the blood; and the monitoring and control system is used for monitoring and controlling operation parameters of the extracorporeal circulation system in real time. According to the system, the blood damage degree can be reduced, the oxygenation efficiency can be improved, and circulation parameters can be accurately controlled and monitored, so that the safety and health of a patient in the extracorporeal circulation process are ensured.

The invention relates to the technical field of hemodialysis, in particular to an anticoagulation modification method of a hemodialyzer, which comprises the following steps: preparing heparinoid, putting the heparinoid into a buffer solution, adding absolute ethyl alcohol and dicyclohexylcarbodiimide, uniformly stirring, adding 3-aminopropyltriethoxysilane and N, N-dimethylacetamide, heating and stirring for reaction, adding a catalyst, stirring for reaction, adding a catalyst, and stirring for reaction to obtain the anticoagulation modified hemodialyzer. Cooling, adding lysine, and continuously stirring to react, so as to obtain an anticoagulant modified solution; and injecting the anticoagulation modification liquid into a dialysis membrane pipeline of the hemodialyzer, and after reaction modification is finished, cleaning and drying the dialysis membrane pipeline to obtain the hemodialyzer with the anticoagulation function. The heparinoid polymer with a sulfonic acid group and a carboxylic acid group is synthesized, and the heparinoid polymer and lysine are fixed in the dialysis membrane through amidation reaction of the heparinoid polymer with lysine and 3-aminopropyltriethoxysilane and self-polycondensation of a reaction product. Therefore, the dialysis membrane has good anticoagulation, thrombus solubility and use stability.

Provided is an intermediate system that, when a CRRT system is connected to an ECMO system, is capable of reducing the effect of pressure received by the CRRT system from the ECMO system. An intermediate system (300) provided to a connection site between an ECMO system (100) and a CRRT system (200), the upstream end of the CRRT system (200) being connected downstream of an ECMO blood pump (120) in the ECMO system (100), the intermediate system (300) being provided with: an intermediate blood return line (320), the upstream end of which is connected to the downstream end of the CRRT system (200) and the downstream end of which is connected to the ECMO system (100); a blood return pump (321); a blood return side pressure buffer section (322) provided upstream of the blood return pump (321); and a control unit (330) that controls the storage amount of the liquid in accordance with the storage state of the return-side pressure buffer unit (322) so that the storage amount falls within a predetermined range.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

The invention belongs to the technical field of medical equipment, and discloses a movable continuous blood purification first-aid device which comprises a movable seat and further comprises a stabilizing mechanism arranged in the inner wall of the bottom end of the movable seat; the blood purification barrel is fixedly connected to the outer wall of the top end of the movable seat, and a cover plate is arranged on the outer wall of the blood purification barrel; the cleaning mechanism is arranged in the inner wall of the blood purification barrel; the mounting mechanism is arranged on the outer wall of the bottom end of the blood purification barrel, and an impurity output pipe is arranged on the inner wall of the mounting mechanism; wherein the stabilizing mechanism comprises a stabilizing plate; through cooperation of the stabilizing plate, the pedal A and other structures, the stabilizing plate can be moved downwards and fixed by treading the pedal A downwards, the stabilizing plate is kept in a state of being in contact with the ground, the overall stability of the device is improved, and then it is guaranteed that in the using process, it is avoided that the device topples over due to external force collision, and the blood purification operation is affected.

Disposable set for an extracorporeal blood treatment apparatus including a blood circuit comprising a filtration unit, a blood withdrawal line including a blood pump tract configured to be engaged by a blood pump, a blood return line, and an infusion line extending between a first end connected to the blood withdrawal line upstream the blood pump tract, and a second end for connection to an infusion substance source: the blood pump tract is interposed between the filtration unit and the first end of the infusion line. The disposable set further comprises a pressure damper arranged towards or at the first end of the infusion line, the pressure damper being configured to prevent, or reduce an amount of, the access negative pressure to extend in the infusion line upstream the pressure damper.

The present document discloses a medical pumping system (20) for moving a fluid through a tube, which may comprise a machine having a motor (24) and a drive mechanism (25), and a pump head configured to be removably coupled to the drive mechanism of the machine. The machine may comprise an inductive sensor (26) and at least one processor (28) connected to the motor and the inductive sensor. The pump head may comprise a metallic element (32) intended to cooperate with the inductive sensor of the machine.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body.

A medical fluid management assembly includes a pneumatic manifold, at least one valve, and a fluid manifold. The pneumatic manifold includes at least one pneumatic passageway that is pneumatically connected to the at least one valve. The fluid manifold includes at least one chamber comprising upper and lower fluid chambers separated by a flexible membrane. The fluid manifold also includes fluid tube sections and fluid pathways that fluidly couple the one or more upper and lower fluid chambers to the at least one valve and at least one of a purified water line, a liquid concentrate line, a to-extracorporeal circuit fresh dialysis fluid line, a drain line, or a from-extracorporeal circuit used dialysis fluid line.